Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights

IPO proceeds expanded liquidity while research spending increased and the EMERGE study began in October.

Rhea-AI Summary

Vogenx (NASDAQ:VOGX) reported a third-quarter 2026 net loss of $4,907,603 as it advanced mizagliflozin development following its August IPO. Loss per basic and diluted share was $0.47, versus $0.05 a year earlier, when net loss was $284,407. Research and development expenses rose to $1,079,000 from $124,813; general and administrative expenses increased to $703,736 from $177,664. A $3,436,669 warrant valuation expense also contributed to the loss.

The IPO generated approximately $84.4 million in net proceeds, with 7,187,500 shares sold at $13.00 each. Cash, cash equivalents and marketable securities totaled $82.1 million at September 30, versus $601 thousand at December 31, 2025. In October, Vogenx initiated the Phase 2b EMERGE study for post-bariatric hypoglycemia, with results expected in the second half of 2027. The company plans a Phase 2 gastroparesis study in the first half of 2027.

7 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointAugust IPO raised approximately $84.4 million in net proceeds after underwriting discounts, commissions and offering expenses. 31% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Mizagliflozin Phase 2b EMERGE began in October; Vogenx expects results in the second half of 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Vogenx plans to initiate a Phase 2 gastroparesis study in the first half of 2027.
• Minor pointCash, cash equivalents and marketable securities reached $82.1 million at September 30, versus $601 thousand at December 31, 2025.
• Minor pointThird-quarter interest income increased to $338,579 from $1,086; nine-month income rose to $338,726 from $5,636 year over year.

2 minor points

• Minor pointTotal liabilities fell to $842,470 at September 30, 2026, from $1,600,405 at December 31, 2025.
• Minor pointStockholders' equity reached $82,000,803 at September 30, 2026, versus a $919,235 deficit at December 31, 2025.

Negative

• Major pointIPO issuance of 7,187,500 common shares at $13.00 each diluted existing holders, including 937,500 underwriter-option shares.
• Moderate pointThird-quarter net loss widened to $4,907,603, or $0.47 per share, from $284,407, or $0.05, a year earlier.
• Moderate pointThird-quarter research and development expenses rose to $1,079,000 from $124,813; nine-month expenses increased to $1,473,697 from $430,517 year over year.
• Moderate pointThird-quarter general and administrative expenses rose to $703,736 from $177,664; nine-month expenses increased to $1,127,576 from $554,818 year over year.
• Minor pointNine-month net loss widened to $5,767,485, or $0.82 per share, from $935,823, or $0.17, a year earlier.

2 minor points

• Minor pointThird-quarter warrant valuation expense was $3,436,669, versus $16,984 income; nine-month expense was $3,426,761, versus $43,876 income a year earlier.
• Minor pointRelated-party convertible-note valuation expense reached $26,777 for the quarter and $78,177 for nine months, versus none a year earlier.

Key Figures

IPO size: $93.4 million Cash, equivalents and marketable securities: $82.1 million R&D expenses: $1.1 million +5 more

IPO size

$93.4 million

Completed in August 2026

Cash, equivalents and marketable securities

$82.1 million

September 30, 2026; versus $601 thousand at December 31, 2025

R&D expenses

$1.1 million

Three months ended September 30, 2026; versus $125 thousand in 2025

Net loss

$4.9 million

Three months ended September 30, 2026; versus $284 thousand in 2025

Net loss per share

$(0.47)

Basic and diluted, third quarter 2026; versus $(0.05) in 2025

EMERGE study participants

Approximately 36 adults

Phase 2b study in post-bariatric hypoglycemia

Treatment duration

28 days

EMERGE study

Topline results timing

Second half of 2027

EMERGE study

Historical Context

1 past event · Latest: Aug 17

1 event

1. Aug 17

   IPO pricing

   24h Move

   +6.6%

   The earlier IPO record listed 6.25 million shares; this report states 7.1875 million after full option exercise.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

post-bariatric hypoglycemia, placebo-controlled, double-blind, warrant liability

4 terms

post-bariatric hypoglycemia medical

"evaluating mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 adults with PBH"

Post-bariatric hypoglycemia is a condition of abnormally low blood sugar that can occur after weight-loss surgery, driven by faster food passage and an exaggerated insulin response. For investors, it matters because the condition can create steady demand for diagnostics, monitoring devices, medications and specialist care, affect clinical trial design and regulatory scrutiny, and alter long-term cost and reimbursement dynamics—like a new problem that creates a market for fixes.

placebo-controlled technical

"a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

double-blind technical

"a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

warrant liability financial

"Change in fair value of warrant liability"

Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RALEIGH, NC / ACCESS Newswire / November 6, 2026 / Vogenx, Inc. (NASDAQ:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update.

"Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August," said James Green, Chief Executive Officer of Vogenx. "The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis."

Recent Corporate & Clinical Highlights

Clinical Pipeline Update:

In October 2026, the Company initiated EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study evaluating mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 adults with PBH. The EMERGE study will be conducted at multiple centers in the United States, with topline results expected in the second half of 2027. The Company plans to initiate a Phase 2 study of mizagliflozin for gastroparesis in the first half of 2027.

Initial Public Offering:

In August 2026, the Company completed its $93.4 million IPO, pursuant to which the Company issued and sold 7,187,500 shares of its common stock at a public offering price of $13.00 per share, including 937,500 additional shares of its common stock pursuant to the exercise in full by the underwriter of its option to purchase shares of common stock from the Company at the IPO price. After deducting underwriting discounts, commissions and offering expenses payable by the Company, the Company received net proceeds from the IPO of approximately $84.4 million.

Leadership and Board Updates:

In September 2026, Ken Toombs was appointed as an independent member of the Vogenx board of directors and chair of the audit committee. In October 2026, Rich Gorman joined the Vogenx management team as Chief Commercial Officer concurrently with his resignation as an independent member of the board of directors, effective October 12, 2026. Mr. Gorman will lead commercial operations, corporate strategy and business development.

Financial Highlights

• Cash Position: As of September 30, 2026, the Company's cash, cash equivalents, and marketable securities totaled $82.1 million, compared to $601 thousand as of December 31, 2025. This significant increase was secured through net proceeds from the Company's August 2026 IPO.
• Research and Development (R&D) Expenses: R&D expenses for the three months ended September 30, 2026, rose to $1.1 million, compared to $125 thousand for the same period in 2025. The increase was primarily driven by $714 thousand in direct program expenses for the PBH EMERGE Phase 2b study and expanded department headcount.
• General and Administrative (G&A) Expenses: G&A expenses for the three months ended September 30, 2026, were $704 thousand, compared to $178 thousand for the three months ended September 30, 2025. The increase reflects $237 thousand in personnel costs and $214 thousand in incremental public company operational expenses.
• Net Loss and EPS: Net loss for the three months ended September 30, 2026, was $4.9 million, or $(0.47) per basic and diluted share, compared to a net loss of $284 thousand, or $(0.05) per basic and diluted share, for the same period in 2025. The net loss for the quarter was the result of operating expenses of $1.8 million, the change in warrant liability of $3.4 million offset by interest income of $0.3 million.

About Vogenx, Inc.

Vogenx, Inc. (Nasdaq:VOGX) is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases with high unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the design, conduct, enrollment, timing and results of the EMERGE Phase 2b study, including the expected timing of topline data; the potential of mizagliflozin to treat post-bariatric hypoglycemia and other indications; anticipated clinical development plans and timelines; the anticipated use of proceeds from the Company's initial public offering, and its capital requirements and need for additional financing; and the potential market opportunity for its product candidates. Words such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the initiation, timing, enrollment and results of clinical trials, the possibility that results of earlier studies may not be predictive of later studies, regulatory review, competition, including the possibility that competitors obtain regulatory approval before the Company, reliance on third parties including clinical research organizations and clinical trial sites, the Company's license from Kissei Pharmaceutical Co., Ltd., the Company's need for additional capital, its limited operating history, its dependence on a small number of key personnel, and the material weaknesses identified in its internal control over financial reporting. Additional information on these and other risks is contained in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Quarterly Report on Form 10-Q for quarter ended June 30, 2026 filed with the SEC on September 17, 2026. Forward-looking statements speak only as of the date of this release, and Vogenx undertakes no obligation to update them except as required by law.

Vogenx, Inc.
Condensed Balance Sheets
Unaudited

		September 30, 2026				December 31, 2025
Assets
Current assets
Cash and cash equivalents		$	5,126,137			$	601,010
Deferred offering costs			-				63,363
Marketable securities			76,991,943				-
Prepaid expenses and other current assets			725,193				16,797
Total current assets			82,843,273				681,170
Total assets		$	82,843,273			$	681,170
Liabilities and stockholders' equity (deficit)
Current liabilities
Accounts payable		$	523,570			$	62,964
Accrued expenses			318,900				709,818
Warrant liability			-				11,323
Convertible promissory notes payable, related party			-				816,300
Total current liabilities			842,470				1,600,405
Total liabilities			842,470				1,600,405
Total stockholders' equity (deficit)			82,000,803				(919,235	)
Total liabilities and stockholders' equity (deficit)		$	82,843,273			$	681,170

Vogenx, Inc.
Condensed Statements of Operations
(Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Operating expenses
Research and development		$	1,079,000			$	124,813			$	1,473,697			$	430,517
General and administrative			703,736				177,664				1,127,576				554,818
Total operating expenses			1,782,736				302,477				2,601,273				985,335
Other (expense) income
Change in fair value of warrant liability			(3,436,669	)			16,984				(3,426,761	)			43,876
Change in fair value of convertible promissory notes payable, related party			(26,777	)			-				(78,177	)			-
Interest income			338,579				1,086				338,726				5,636
Total other (expense) income			(3,124,867	)			18,070				(3,166,212	)			49,512
Net loss		$	(4,907,603	)		$	(284,407	)		$	(5,767,485	)		$	(935,823	)
Net loss per common share - basic and diluted		$	(0.47	)		$	(0.05	)		$	(0.82	)		$	(0.17	)
Weighted average common shares outstanding - basic and diluted			10,404,831				5,451,873				6,995,883				5,451,873

Contact

Harrison Seidner, PhD and Nilesh Talele, PhD
WaterSeid Partners, Inc.
ir@vogenx.com

SOURCE: Vogenx, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Vogenx's third-quarter 2026 earnings results?

Vogenx reported a $4,907,603 net loss, or $0.47 per basic and diluted share, for the three months ended September 30, 2026. That compares with a $284,407 loss, or $0.05 per basic and diluted share, in the same period of 2025.

When does Vogenx expect results from the EMERGE study?

Vogenx expects topline results from the Phase 2b EMERGE study in the second half of 2027. The study began in October 2026 and evaluates mizagliflozin for post-bariatric hypoglycemia.

How is Vogenx's Phase 2b EMERGE trial designed?

EMERGE is a randomized, placebo-controlled, double-blind, parallel-group study evaluating mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 adults with post-bariatric hypoglycemia. It will be conducted at multiple United States centers.

What drove Vogenx's higher third-quarter operating expenses?

Higher research spending primarily reflected $714 thousand in direct EMERGE program expenses and expanded department headcount. The increase in general and administrative expenses reflected $237 thousand in personnel costs and $214 thousand in incremental public-company operational expenses.